Evaluation of Adverse Effects of Lisinopril and Rosuvastatin on Hematological and Biochemical Analytes in Wistar Rats
Keywords:Lisinopril, rosuvastatin, toxicity evaluation
AbstractObjective: Combination therapy of lisinopril and rosuvastatin may be an important concept in developing more effective strategies to treat and prevent atherosclerosis, coronary heart disease, and co"‘morbid metabolic disorders. The present study was designed to evaluate toxic effects of lisinopril and rosuvastatin alone or its combination therapy on hematological and biochemical analytes in Wistar rats. Materials and Methods: Forty"‘two rats were divided into seven groups, with each group comprising six rats. Rats were administered with lisinopril, rosuvastatin alone, or in"‘combination at two different doses. The blood samples were collected from rats after 21 days of oral administration of the drug/s and analyzed for various hematological and biochemical analytes. Results: Lisinopril alone and its combination treatment with rosuvastatin at high doses decreased hemoglobin and hematocrit. Rosuvastatin alone at high dose and its concomitant administration with lisinopril at two different doses showed increase in total white blood cells and absolute lymphocyte count and neutrophil count. Serum levels of aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin were significantly increased in rosuvastatin alone and its combination with lisinopril at both the doses. Besides this, lisinopril treatment decreased serum levels of sodium and increased the levels of potassium. Serum creatine kinase (CK) levels were increased in the animals treated with rosuvastatin at both the doses. However, increased serum CK level because of rosuvastatin became normal with co"‘administration of lisinopril at low doses. Conclusion: Our results indicate that administration of lisinopril with rosuvastatin does not ameliorate hepatotoxicity caused by rosuvastatin. However, combination treatment reduces serum CK levels elevated due to rosuvastatin, implicating protective effect of combination treatment on myopathy at low doses.
Gupta R, Guptha S, Sharma KK, Gupta A, Deedwania P. Regional variations in cardiovascular risk factors in India: India heart watch. World J Cardiol 2012;4:112"‘20.
Koh KK. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000;47:648"‘57.
Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms. Circulation 2006;113:1888"‘904.
Koh KK, Han SH, Oh PC, Shin EK, Quon MJ. Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid"‘RAAS interaction. Atherosclerosis 2010;209:307"‘13.
Nickenig G. Should angiotensin II receptor blockers and statins be combined? Circulation 2004;110:1013"‘20.
Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, et al. Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol 2004;95:185"‘91.
Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905"‘10.
Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK.Anti"‘inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006;108:96"‘100.
Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: Insights from therapeutic interventions.J Am Coll Cardiol 2005;46:1978"‘85.
Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: Response to therapeutic interventions. J Am Coll Cardiol 2007;49:531"‘8.
Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, Kim HS, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45:1088"‘93.
Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, et al. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol 2010;299:F1203"‘11.
Product Monograph of Zestril® (Lisinopril), Astrazeneca Canada Inc., 2009. Available from: http://www.asterazeneca/ documents/product portfolio/Zestril_PM_en.pdf [Last dated on 2013 Jan 4].
Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin"‘associated adverse effects and drug"‘drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010;10:11"‘28.
Kawamura M, Imanishi M, Matsushima Y, Akabane S, Kuramochi M, Ito K, et al. A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans.Jpn J Pharmacol 1990;54:143"‘9.
Kabour A, Henegar JR, Devineni VR, Janicki JS. Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res 1995;29:543"‘8.
Shinosaki T, Takagawa I, Sunagawa N, Yonetani Y, Kurihara H.Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats. Jpn J Pharmacol 1997;73:337"‘45.
Review and evaluation of pharmacology and toxicology dataof rosuvastatin. Advisory Committee Briefing Document. July 9: 2003. Available from: http://www.fda.gov [Last dated on 2013 Jan 4].
Tiwari A. An overview of statin"‘associated proteinuria. Drug Discov Today 2006;11:458"‘64.
Dodiya H, Jain M, Goswami SS. Renal toxicity of lisinopril and rosuvastatin, alone and in combination, in Wistar rats. Int J Toxicol 2011;30:518"‘27.
Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18:781"‘8.
Conforti A, Chiamulera C, Moretti U, Colcera S, Fumagalli G, Leone R. Musculoskeletal adverse drug reactions: A review of literature and data from ADR spontaneous reporting databases.Curr Drug Saf 2007;2:47"‘63.
Nomura S, Sugihara T, Tomiyama T, Kitano Y, Yawata Y, Osawa G. Polycythaemia vera: Response to treatment with angiotensin"‘converting enzyme inhibitor. Eur J Haematol 1996;57:117"‘9.
Pharmacology Review(s) of Crestor (Rosuvastatin Calcium), Astra Zeneca Pharmaceuticals, Drug Approval Pacakge, 2003. Available from: http://www.accessdata.fda.gov/drugsatfda_ docs/nda/2003/21"‘366_Crestor.cfm [Last dated on 2013 Jan 4].
Gokcimen A, Kocak A, Kilbas S, Bayram D, Kilbas A, Cim A, et al. Effect of lisinopril on rat liver tissues in L"‘NAME induced hypertension model. Mol Cell Biochem 2007;296:159"‘64.
Izzedine H, Fardet L, Launay"‘Vacher V, Dorent R, Petitclerc T, Deray G. Angiotensin"‘converting enzyme inhibitor"‘induced syndrome of inappropriate secretion of antidiuretic hormone: Case report and review of the literature. Clin Pharmacol Ther 2002;71:503"‘7.
Rose BD, Post TW. Clinical Physiology of Acid"‘Base and Electrolyte Disorders, 5th ed. New York: McGraw"‘Hill, Inc.; 2001.p. 703"‘11.
Warren SE, O'Connor DT. Hyperkalemia resulting from captopril administration. JAMA 1980;244:2551"‘2.
Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH.Lipid"‘lowering drugs and risk of myopathy: A population"‘based follow"‘up study. Epidemiology 2001;12:565"‘9.
Shek A, Ferrill MJ. Statin"‘fibrate combination therapy. Ann Pharmacother 2001;35:908"‘17.
Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin"‘associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581"‘5.
Thompson PD, Clarkson P, Karas RH. Statin"‘associated myopathy.JAMA 2003;289:1681"‘90.
Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol 2006;97:52"‘60C.